肿瘤教化血小板转录组中miRNA区分肺结节良、恶性的可行性研究进展

Research progress in the feasibility study of miRNA in tumor-educated platelet transcriptome to distinguish benign and malignant pulmonary nodules

肺癌是世界上致死率最高的恶性肿瘤之一,液体活检是目前肿瘤研究的热点,已有部分应用于临床,具有早期筛查、定期检测疗效、预测预后等优势。其中肿瘤教化血小板作为新型液体活检标志物来源,是目前用于检测早期NSLCL的热门生物标志物,可通过分析肿瘤教化血小板的转录组可以区分健康人与肺癌患者。而目前发现部分miRNA在肺结节的良恶性鉴别方面有着重要意义。本文就肿瘤教化血小板转录组中miRNA区分肺结节良、恶性的可行性研究进展进行综述。

Lung cancer is one of the most lethal malignant tumors in the world. Liquid biopsy is a hotspot of tumor research at present. It has been partially applied in clinical practice with advantages of early screening, regular detection of efficacy and prognosis prediction. As a new source of liquid biopsy markers, tumor-educated platelets are currently a popular biomarker used to detect early NSCLC, and the transcriptome analysis of tumor cultured platelets can distinguish healthy people from lung cancer patients. Currently, some mirnas have been found to be of great significance in the differentiation of benign and malignant pulmonary nodules. This paper reviews the feasibility of differentiating benign and malignant pulmonary nodules by miRNA in tumor-educated platelet transcripts.